The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis

Purpose Three dopamine agonists [bromocriptine, cabergoline, and quinagolide (CV)] have been used for hyperprolactinemia treatment for decades. Several studies have reviewed the efficacy and safety of bromocriptine and cabergoline. However, no systematic review or meta-analysis has discussed the efficacy and safety of CV in hyperprolactinemia and prolactinoma treatment. Methods Five medical databases (PubMed, Web of Science, Embase, Scopus, and Cochrane Library) were searched up to 9 May 2022 to identify studies related to CV and hyperprolactinemia. A meta-analysis was implemented by using a forest plot, funnel plot, sensitivity analysis, meta-regression, and Egger’s test via software R 4.0 and STATA 12. Results A total of 1,211 studies were retrieved from the five medical databases, and 33 studies consisting of 827 patients were finally included in the analysis. The pooled proportions of patients with prolactin concentration normalization and tumor reduction (>50%) under CV treatment were 69% and 20%, respectively, with 95% confidence intervals of 61%–76% and 15%–28%, respectively. The pooled proportion of adverse effects was 13%, with a 95% confidence interval of 11%–16%. Conclusion Our study showed that CV is not less effective than cabergoline and bromocriptine in treating hyperprolactinemia, and the side effects were not significant. Hence, this drug could be considered an alternative first-line or rescue treatment in treating hyperprolactinemia in the future. Systematic review registration https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022347750.

[1]  Paras B. Khandhar,et al.  Double Blind Study , 2019 .

[2]  P. Chanson,et al.  The epidemiology, diagnosis and treatment of Prolactinomas:The old and the new. , 2019, Best practice & research. Clinical endocrinology & metabolism.

[3]  W. Drake,et al.  A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline , 2018, The Journal of clinical endocrinology and metabolism.

[4]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[5]  S. Lin,et al.  Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis , 2017, Endocrine.

[6]  S. Yarman,et al.  Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? , 2016, Pituitary.

[7]  Jintao Hu,et al.  Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis , 2015, Pituitary.

[8]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[9]  A. Klibanski,et al.  Clinical practice. Prolactinomas. , 2010, The New England journal of medicine.

[10]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[11]  O. Dekkers,et al.  Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. , 2010, The Journal of clinical endocrinology and metabolism.

[12]  C. E. Cervantes,et al.  [Cabergoline in hyperprolactinemia and valvular heart disease]. , 2009, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

[13]  S. Savastano,et al.  Medical therapy of pituitary adenomas: Effects on tumor shrinkage , 2009, Reviews in Endocrine and Metabolic Disorders.

[14]  Elena S. Di Martino,et al.  Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A metaanalysis from clinical studies , 2008, Journal of endocrinological investigation.

[15]  L. Ginsberg,et al.  Quinagolide in the Management of Prolactinoma , 2000, Pituitary.

[16]  S. Melmed.  Mechanisms for pituitary tumorigenesis: the plastic pituitary. , 2003, The Journal of clinical investigation.

[17]  V. Rohmer,et al.  Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. , 2000, Annales d'endocrinologie.

[18]  J. I. Botella,et al.  A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients , 2000, Journal of endocrinological investigation.

[19]  P. Marzullo,et al.  The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas , 2000, Clinical endocrinology.

[20]  A. Colao,et al.  Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin‐secreting and clinically non‐functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I‐methoxybenzamide , 2000, Clinical endocrinology.

[21]  S. Loche,et al.  Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. , 1998, The Journal of clinical endocrinology and metabolism.

[22]  A. Colao,et al.  Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. , 1996, European journal of endocrinology.

[23]  A. Barlier,et al.  Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. , 1996, European journal of endocrinology.

[24]  P. Marzullo,et al.  Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. , 1995, Hormone research.

[25]  C. Burke,et al.  Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine , 1994, Clinical endocrinology.

[26]  C. Nappi,et al.  Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. , 1994, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[27]  P. Marzullo,et al.  CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. , 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[28]  M. Giusti,et al.  A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients , 1994, Journal of endocrinological investigation.

[29]  T. Bjøro,et al.  Long-term treatment of macroprolactinomas with CV 205-502. , 1993, Acta endocrinologica.

[30]  R. Lappöhn,et al.  The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. , 1992, Fertility and sterility.

[31]  D. Dewailly,et al.  Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. , 1992, The Journal of clinical endocrinology and metabolism.

[32]  I. Morange,et al.  Prolactinomas and resistance to dopamine agonists. , 1992, Hormone research.

[33]  A. Luger,et al.  [Treatment of prolactinoma with a new dopamine agonist]. , 2008, Deutsche medizinische Wochenschrift.

[34]  A. Grossman,et al.  Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study. , 1991, Acta endocrinologica.

[35]  M. Reymond,et al.  CV 205–502 treatment of macroprolactinomas , 1991, Journal of endocrinological investigation.

[36]  T. Bergh,et al.  Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. , 1991, Acta endocrinologica.

[37]  J. Schoemaker,et al.  CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[38]  S. Lamberts,et al.  The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. , 1991, Journal of Clinical Endocrinology and Metabolism.

[39]  Z. Shoham,et al.  CV 205-502--effectiveness, tolerability, and safety over 24-month study. , 1991, Fertility and sterility.

[40]  P. Chanson,et al.  Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine‐resistant prolactinomas , 1991, Clinical endocrinology.

[41]  J. W. Verlaat,et al.  TREATMENT OF MACROPROLACTINOMAS WITH A NEW NON‐ERGOT, LONG‐ACTING DOPAMINERGIC DRUG, CV 205–502 , 1990, Clinical endocrinology.

[42]  L. Pedneault,et al.  Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas. , 1990, The Journal of clinical endocrinology and metabolism.

[43]  B. Claustrat,et al.  Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas. , 1990, The Journal of clinical endocrinology and metabolism.

[44]  H. Jacobs,et al.  A DOUBLE‐BLIND STUDY COMPARING A NEW NON‐ERGOT, LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, WITH BROMOCRIPTINE IN WOMEN WITH HYPERPROLACTINAEMIA , 1990 .

[45]  M. Vance,et al.  Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. , 1990, Annals of internal medicine.

[46]  R. Rolland,et al.  The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study. , 1989, Fertility and sterility.

[47]  M. Vance,et al.  CV 205-502 treatment of hyperprolactinemia. , 1989, The Journal of clinical endocrinology and metabolism.

[48]  L. Wide,et al.  LONG‐TERM TREATMENT WITH A NEW NON‐ERGOT LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, IN WOMEN WITH HYPERPROLACTINAEMIA , 1988, Clinical endocrinology.

[49]  M. Kathol,et al.  Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. , 1987, The Journal of clinical endocrinology and metabolism.

[50]  S E Brooks,et al.  The Old and the New , 1972, Social Service Review.